Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SanBio Company Limited (4592.T)
JPY1,050.00
+42.00 (+4.17%)
JP JPX Healthcare Biotechnology
Address
St. Luke Tower 104-0044
Tokyo, JP
Tokyo, JP
CEO
Keita Mori
Website
sanbio.jp
IPO
2015-04-08
ISIN JP3336750009
Also trades on
Other OTC · SNBIF (USD)
Tokyo Stock Exchange · 4592.T (JPY)
Description
SanBio Company Limited is dedicated to the creation, production, and sale of regenerative cell therapies, primarily concentrated on disorders of the central nervous system. A central component of their portfolio is SB623, a treatment that has completed Phase 2 clinical trials in both the United States and Japan for traumatic brain injury. Beyond this, their comprehensive research pipeline explores the broader potential of SB623 for conditions such as ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease. The company's development efforts also encompass other innovative treatments: SB618 for peripheral nerve damage, SB308 for muscular dystrophy, MSC1 for cancer, and MSC2 for inflammatory diseases and optic neuritis. Founded in 2001, SanBio maintains its corporate headquarters in Tokyo, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY1,050.00
+42.00 (+4.17%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.28
Float Shares
58.83M
Free Float %
75.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.98% | -0.32% | -31.86% | -38.15% | -25.89% | -24.62% | -61.68% | +102.63% | -16.17% | -35.19% | -30.40% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1,050.00
DCF (Unlevered)
189.35
-82.0%
DCF (Levered)
189.35
-82.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 5 | +1 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
31.00
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-25.5% Q2'26: +49.9% (vs Q2'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q2'26: +2,722.6% (vs Q2'25)
-
Share dilution Biotechnology: -3.4%+6.2% Q2'26: +8.9% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.29× Q2'26: -0.31× (vs Q2'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Jan 2016 actual |
Jan 2017 actual |
Jan 2018 actual |
Jan 2019 actual |
Jan 2020 actual |
Jan 2021 actual |
Jan 2022 actual |
Jan 2024 actual |
Jan 2025 actual |
Jan 2026 3 Rev. Ana. 5 EPS Ana. |
Jan 2027 1 Rev. Ana. 1 EPS Ana. |
Jan 2028 5 Rev. Ana. 4 EPS Ana. |
Jan 2029 5 Rev. Ana. 4 EPS Ana. |
Jan 2030 2 Rev. Ana. 2 EPS Ana. |
Jan 2031 1 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.17B
est: 1.48B (-20.8%)
|
949.54M
est: 934.25M (+1.6%)
|
490.51M
est: 650.00M (-24.5%)
|
741.61M
est: 741.25M (+0.0%)
|
447.23M
est: 492.17M (-9.1%)
|
—
est: 602.40M (-100.0%)
|
—
est: 175.00M (-100.0%)
|
—
est: 791.67M (-100.0%)
|
—
est: 200.00M (-100.0%)
|
250.00M
15.95M – 1.11B
+25.0% YoY
|
1.72B
109.76M – 7.62B
+588.0% YoY
|
15.27B
600.00M – 69.05B
+787.8% YoY
|
19.31B
19.31B – 19.31B
+26.5% YoY
|
8.08B
515.74M – 35.82B
-58.1% YoY
|
11.81B
753.76M – 52.35B
+46.2% YoY
|
| EBITDA |
-1.11B
|
-1.91B
|
-4.32B
|
-3.70B
|
-5.45B
|
-5.73B
|
-4.37B
|
-2.50B
|
-2.98B
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-1.13B
|
-1.93B
|
-4.38B
|
-3.73B
|
-5.49B
|
-5.80B
|
-4.51B
|
-2.52B
|
-2.99B
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-988.40M
est: -1.60B (+38.3%)
|
-1.84B
est: -2.89B (+36.5%)
|
-3.94B
est: -4.11B (+4.2%)
|
-2.92B
est: -4.36B (+33.0%)
|
-5.16B
est: -6.43B (+19.7%)
|
-3.39B
est: -8.04B (+57.9%)
|
-4.68B
est: -6.78B (+31.0%)
|
-2.64B
est: -2.17B (-22.1%)
|
-2.88B
est: -3.57B (+19.2%)
|
-3.84B
-4.23B – -3.22B
-7.6% YoY
|
-5.23B
-22.12B – 878.97M
-36.1% YoY
|
1.26B
567.50M – 1.55B
+124.0% YoY
|
1.96B
1.01B – 2.52B
+55.9% YoY
|
-1.55B
-8.47B – 336.43M
-179.1% YoY
|
3.81B
-826.80M – 20.81B
+345.8% YoY
|
| SGA |
589.96M
|
779.50M
|
659.13M
|
635.93M
|
1.57B
|
1.66B
|
1.53B
|
1.68B
|
1.15B
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-22.66
est: -23.27 (+2.6%)
|
-40.88
est: -41.99 (+2.6%)
|
-86.84
est: -59.70 (-45.5%)
|
-60.16
est: -63.25 (+4.9%)
|
-100.89
est: -93.31 (-8.1%)
|
-65.38
est: -116.76 (+44.0%)
|
-90.33
est: -98.44 (+8.2%)
|
-40.48
est: -56.03 (+27.7%)
|
-41.86
est: -47.83 (+12.5%)
|
-53.83
-57.87 – -44.06
-12.6% YoY
|
-55.39
-302.51 – 12.02
-2.9% YoY
|
15.22
7.76 – 21.26
+127.5% YoY
|
24.13
13.75 – 34.51
+58.5% YoY
|
-21.20
-115.79 – 4.60
-187.9% YoY
|
52.10
-11.31 – 284.55
+345.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-10 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-09 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-03 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-02 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.79
OE per share TTM
0.00
Owner's Yield
0.00%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
44.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 43 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.03% | 164.4K | 0.58% |
| 2 | iShares MSCI Japan Small-Cap ETF SCJ | 0.03% | 73.7K | 0.50% |
| 3 | State Street SPDR S&P International Small Cap ETF GWX | 0.02% | 147.7K | 0.40% |
| 4 | iShares International Small-Cap Equity Factor ETF ISCF | 0.01% | 90.6K | 0.24% |
| 5 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.01% | 22.4K | 0.83% |
| 6 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.01% | 1.35M | 0.40% |
| 7 | iShares Core MSCI Japan IMI UCITS ETF SJPE.AS | 0.00% | 6.3K | 0.17% |
| 8 | iShares Core MSCI Japan IMI UCITS ETF IJPA.L | 0.00% | 379.6K | 0.12% |
| 9 | iShares Core MSCI Japan IMI UCITS ETF SJPD.AS | 0.00% | 3.0K | 0.12% |
| 10 | BMO MSCI EAFE Small-Mid Cap Index ETF ZESM.TO | 0.00% | 11.7K | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
Shares Outstanding
78.04M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dai Chida | Senior Scientific Advisor | — | male |
| Kazumi Sawaguchi | Corporate Officer and Head of Japan Regulatory Affairs & Quality Compliance Japan | — | — |
| Keita Mori | Co-Founder, President, Executive Officer, Chief Executive Officer & Representative Director | — | male |
| Munetaka Nobeyama | Executive Officer, Head of Reliability Assurance & Regulatory Affairs Division | — | — |
| Naoki Tsukahara | Senior Corporate Officer | — | male |
| Shinya Hirata | Corporate Officer & Head of Research and Development | — | male |
| Soyoku Nobeyama | Corporate Officer, Head of Japan Regulatory Affairs & Quality Compliance Japan | — | male |
| Tetsuya Isono | Corporate Officer & Head of Production | — | male |
| Toru Kawanishi | Co-Founder & Executive Chairman | — | male |
| Yoshihiro Kakutani | Corporate Officer of Management Administration | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4592.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
